Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

Inclusion Criteria Concurrent Medication: Allowed: * G-CSF. * Licensed or Treatment IND-approved antiretrovirals ( AZT, ddI, ddC, d4T ). * PCP prophylaxis (required if CD4 count \< 200 cells/mm3). * Chemoprophylaxis or maintenance for bacterial infections, candidiasis, MAC, and herpes simplex. * Up to 14 days of metronidazole. * Recombinant erythropoietin. Patients must have: * Documented HIV infection. * Advanced stage Kaposi's sarcoma. * No active acute opportunistic infection. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Significant pulmonary insufficiency (unless due to pulmonary KS). * Significant cardiac insufficiency. * Other active malignancies except for basal or squamous cell carcinoma of the skin or in situ cervical cancer. * Grade 2 or worse peripheral neuropathy. * Altered mental status that prevents informed consent. * Active Mycobacterium tuberculosis. * Hypersensitivity or allergic reaction to any study drugs or E. coli-derived medications such as filgrastim (G-CSF). Concurrent Medication: Excluded: * GM-CSF. * Drugs associated with peripheral neuropathy (other than approved antiretrovirals and vincristine). * Multi-drug therapy for active Mycobacterium tuberculosis (although isoniazid and pyridoxine is allowed as treatment for a positive PPD, with permission of study chair). Concurrent Treatment: Excluded: * Radiation therapy to study marker lesions. Patients with the following prior condition are excluded: * Neuropsychiatric history. Prior Medication: Excluded: * Any anti-KS therapy within 21 days prior to study entry. * Prior systemic therapy with any anthracycline (including liposomal anthracyclines), vincristine, or bleomycin. * Any investigational drug (other than those available through Treatment IND and used for FDA-sanctioned purposes) within 14 days prior to study entry. PER AMENDMENT 11/29/95: * No more than 2 cycles of any systemic chemotherapy for Kaposi's sarcoma.